Akorn, Inc. is a niche pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals as well as animal and consumer health products. It specializes in difficult-to-manufacture sterile and non-sterile dosage forms including: ophthalmics, injectables, oral liquids, otics, topicals, inhalants, and nasal sprays. Akorn markets its products to retail pharmacies, ophthalmologists, optometrists, physicians, veterinarians, hospitals, clinics, wholesalers, distributors, group purchasing organizations, and government agencies.
Akorn was acquired by Fresenius Kabi AG on April 24, 2017.

Company Growth (employees)
Type
Public
Parent Company
Fresenius Kabi
HQ
Lake Forest, US
Founded
1948
Size (employees)
2,261 (est)
Website
akorn.com
Akorn was founded in 1948 and is headquartered in Lake Forest, US

Akorn Office Locations

Akorn has offices in Lake Forest, Ann Arbor, Gurugram, Jersey and in 3 other locations
Lake Forest, US (HQ)
300 1925 W Field Ct
Ann Arbor, US
2929 Plymouth Rd
Gurugram, IN
DLF Building Number 9B
Show all (7)

Akorn Financials and Metrics

Akorn Financials

Akorn's revenue was reported to be $1.1 b in FY, 2016
USD

Revenue (Q3, 2017)

202.4 m

Gross profit (Q3, 2017)

98 m

Gross profit margin (Q3, 2017), %

48%

Net income (Q3, 2017)

(2.9 m)

EBIT (Q3, 2017)

9.4 m

Market capitalization (22-Dec-2017)

4 b

Cash (30-Sep-2017)

345.4 m

EV

4.5 b
Akorn's current market capitalization is $4 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

317.7 m593.1 m985.1 m1.1 b

Revenue growth, %

87%66%13%

Cost of goods sold

145.8 m295.5 m105.5 m442.6 m

Gross profit

171.9 m297.6 m879.5 m674.3 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

81.9 m90.6 m150.7 m132.7 m227.4 m220.9 m256.8 m268.3 m280.7 m284.1 m253.4 m199.1 m202.4 m

Cost of goods sold

38.2 m41 m74.1 m81 m97.2 m92.5 m93.8 m105.3 m109 m113.9 m104.3 m96.2 m104.5 m

Gross profit

43.7 m49.7 m76.7 m51.7 m130.2 m128.4 m163 m163 m171.8 m170.2 m149.1 m103 m98 m

Gross profit Margin, %

53%55%51%39%57%58%63%61%61%60%59%52%48%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

34.2 m70.7 m346.3 m200.8 m

Accounts Receivable

283.2 m

Inventories

5.8 m30.9 m20 m174.8 m

Current Assets

168.9 m494.3 m751.2 m685.8 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

75.6 m45.6 m107.9 m131.5 m123.5 m257.1 m314.5 m141 m156.3 m174.1 m307.4 m322.7 m345.4 m

Accounts Receivable

61.5 m65.5 m140 m145.2 m190.7 m130.8 m138.9 m172.2 m205 m263 m233.7 m177.6 m188.8 m

Inventories

56.7 m62 m108.9 m132.8 m149.4 m156.3 m175.9 m190.9 m188 m179.7 m172.3 m181.5 m182.5 m

Current Assets

205.3 m185.7 m397.2 m494.1 m543.9 m607 m698.8 m530 m593.9 m644.2 m736 m703.9 m762.9 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

52.4 m35.3 m37.5 m184.2 m

Depreciation and Amortization

7.4 m44.1 m17.1 m65.7 m

Accounts Receivable

(14 m)

Inventories

(3.8 m)(13 m)2.9 m(6.5 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

12.2 m9.8 m8.5 m(11.7 m)37.5 m70 m118 m41.9 m103.9 m151.8 m41 m43.6 m40.7 m

Depreciation and Amortization

8.6 m14 m21.1 m44.7 m63.8 m22.5 m44.1 m66 m20.9 m42.2 m63.8 m

Accounts Receivable

(21.4 m)(54.3 m)(112.3 m)49.6 m105.8 m94.5 m

Accounts Payable

37.8 m36.7 m7.9 m(3.6 m)9.4 m(1.9 m)4.8 m5.7 m(4.3 m)(13.5 m)(1.8 m)
USDY, 2017

EV/EBIT

475.2 x

EV/CFO

21.3 x

Revenue/Employee

89.5 k

Financial Leverage

2.3 x
Show all financial metrics

Akorn Market Value History

Akorn Median Salaries

Source: 75 public H-1B filings from Akorn

Akorn's Web-traffic and Trends

Akorn News and Updates

Fresenius oncology drug plant slammed with new warning letter

A Fresenius Kabi cancer drug plant in India savaged by the FDA in the past for hiding serious drug testing issues, has been branded with a new warning letter.

Fresenius Kabi to invest $100M, add 445 jobs in North Carolina as U.S. investments now top $5B

With plans for a major expansion of its North Carolina site, Fresenius Kabi's investments aimed primarily at the U.S. generics market now top $5 billion as the German drugmaker bets on growth in sterile injectables.

Akorn sterile plant in Illinois smacked again by the FDA

An Akorn sterile injectables plant in Illinois is in hot water with the FDA again, but this time it may be a problem for Fresenius Kabi, which is buying the generics manufacturer in a $4.3 billion deal.

Akorn Company Life and Culture

You may also be interested in